Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Smoking Cessation Label Changes Could Lay Groundwork For Indications

This article was originally published in The Tan Sheet

Executive Summary

FDA drops its requirement for labeling provisions for NRTs on duration of use and concomitant use of tobacco or other NRTs. Meanwhile, the agency rejects citizen petition requests for additional NRT indications, but says it is open to working with sponsors on developing those indications.

You may also be interested in...



Wider Options In FDA's NRT Clinical Trial Guidance, Approval Path Still Narrow

FDA's NRT clinical draft guidance is latest piece of its evolving strategy for making available more products to help smokers quit. But FDA maintains requirements that keep approval bar high and its separate draft guidance published in 2018 on nonclinical trials put NRT progress on hold, says Saul Shiffman, an OTC switch consultant with work includes multiple NRT proposals.

Nicofi Targets Selling E-Cigarette Users And Smokers On A Substitute

Ross Myles Health is not making a smoking cessation or NRT claim for Nicofi sublingual tablets made with steam-extracted pure nicotine, keeping the product free of drug regulation by FDA. While Nicofi also is outside the agency’s current tobacco product authority, the firm is prepared for FDA oversight.

Nicofi Targets Selling E-Cigarette Users And Smokers On A Substitute

Ross Myles Health is not making a smoking cessation or NRT claim for Nicofi sublingual tablets made with steam-extracted pure nicotine, keeping the product free of drug regulation by FDA. While Nicofi also is outside the agency’s current tobacco product authority, the firm is prepared for FDA oversight.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106321

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel